Literature DB >> 10886114

Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo.

F E Strachan1, T R Crockett, N L Mills, G A Gray, D J Webb.   

Abstract

AIMS: The aim of the study was to examine the effects of the ETB receptor selective agonists sarafotoxin S6c (SFTX6c) and BQ-3020 on the forearm resistance and capacitance vessels in healthy subjects in vivo.
METHODS: The local response to intra-arterial or intravenous infusion of SFTX6c (5 pmol min-1) or BQ-3020 (50 pmol min-1) was assessed, on separate occasions, in eight healthy men (aged 20-28 years). Data (mean +/- s.e.mean) were examined by ANOVA. Results are expressed as percentage change from baseline at 90 min.
RESULTS: SFTX6c and BQ-3020 reduced forearm blood flow, following local intra-arterial infusion (-25 +/- 7% and -27 +/- 7%, respectively; P < 0.001) and reduced hand vein diameter, following local intravenous infusion (-30 +/- 8% and -16 +/- 7%, respectively; P < 0.001).
CONCLUSIONS: We have shown that locally active infusions of the selective ETB receptor agonists SFTX6c and BQ-3020 cause arterial constriction and venoconstriction in healthy human blood vessels in vivo. These results indicate that ETB receptor stimulation may mediate vasoconstriction in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886114      PMCID: PMC2014967          DOI: 10.1046/j.1365-2125.2000.00213.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Cloning and expression of a cDNA encoding an endothelin receptor.

Authors:  H Arai; S Hori; I Aramori; H Ohkubo; S Nakanishi
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men.

Authors:  F E Strachan; J C Spratt; I B Wilkinson; N R Johnston; G A Gray; D J Webb
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.

Authors:  M P Love; W G Haynes; G A Gray; D J Webb; J J McMurray
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

5.  A new technique for recording compliance of human hand veins.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

6.  Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

Authors:  M C Verhaar; F E Strachan; D E Newby; N L Cruden; H A Koomans; T J Rabelink; D J Webb
Journal:  Circulation       Date:  1998-03-03       Impact factor: 29.690

Review 7.  The pharmacology of human blood vessels in vivo.

Authors:  D J Webb
Journal:  J Vasc Res       Date:  1995 Jan-Feb       Impact factor: 1.934

8.  ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit.

Authors:  J P Gratton; G Cournoyer; B M Löffler; P Sirois; P D'Orléans-Juste
Journal:  Hypertension       Date:  1997-11       Impact factor: 10.190

9.  Endothelin is a potent long-lasting vasoconstrictor in men.

Authors:  J G Clarke; N Benjamin; S W Larkin; D J Webb; G J Davies; A Maseri
Journal:  Am J Physiol       Date:  1989-12

10.  Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.

Authors:  W G Haynes; F E Strachan; D J Webb
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

View more
  3 in total

1.  Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.

Authors:  Neeraj Dhaun; Fiona E Strachan; David E Newby; Neil R Johnston; Neville F Ford; Janis L Hammett; Maria Palmisano; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  Endothelin-1 and its receptors on haemorrhoidal tissue: a potential site for therapeutic intervention.

Authors:  Varut Lohsiriwat; John H Scholefield; Vincent G Wilson; Michael R Dashwood
Journal:  Br J Pharmacol       Date:  2017-02-16       Impact factor: 8.739

Review 3.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.